Fate Therapeutics, Inc.
FATENASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $254.04M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.95$3.23
- Volume (live)
- -
- Avg. volume (3M)
- 1.52M
Fate Therapeutics (FATE) Stock Price & Financial Analysis
Fate Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.02 - $2.14 |
|---|---|
| 52-Week High | $3.23 |
| 52-Week Low | $0.95 |
| Open | $2.08 |
| Volume (last close) | 1.11M |
| Average Volume (3M) | 1.52M |
| Revenue (TTM) | 6.49M |
|---|---|
| Net Income (TTM) | -126.00M |
| Free Cash Flow (TTM) | -105.66M |
| EPS (TTM) | −$1.05 |
| Profit Margin | -1941.09% |
| Operating Margin | -2058.08% |
| Return on Equity (ROE) | -82.12% |
| Debt to Equity | 0.49 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 254.04M |
|---|---|
| Shares Outstanding | 120.40M |
| Price to Sales (P/S) | 39.14 |
| Price to Book (P/B) | 1.66 |
| EV/EBITDA | -2.56 |
| 50-Day MA | $2.37 |
|---|---|
| 200-Day MA | $1.92 |
| 1-Year Change | +37.50% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Fate Therapeutics at a Glance
As of the Oct 23, 2026 close, Fate Therapeutics (FATE) has a market capitalization of $254.04M. The stock trades at 39.1× sales. Over the trailing twelve months it lost $126.00M on revenue of $6.49M and burned $105.66M of free cash flow. Revenue fell 23.4% year over year.
As of its latest reported balance sheet, it holds $32.43M in cash and securities against $75.67M of debt, a net debt position of $43.25M.
Fate Therapeutics does not currently pay a dividend.
The share price is up 37.5% over the past year. At $2.11 (the Oct 23, 2026 close) it sits within its 52-week range of $0.95 to $3.23, above its 200-day moving average of $1.92.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $6.63, 214.2% above the Oct 23, 2026 close.
Frequently Asked Questions About Fate Therapeutics
What is the current stock price for FATE?
As of the Oct 23, 2026 close, FATE stock trades at $2.11. The 52-week range is $0.95–$3.23, with a day range of $2.02–$2.13.
What is the P/E ratio for FATE?
The P/E ratio (Price-to-Earnings) for FATE is shown in the Key Statistics section. This valuation metric helps compare Fate Therapeutics, Inc. to industry peers.
Does FATE pay dividends?
Fate Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for FATE?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for FATE is Buy. The average 12-month price target is $6.63, a 214.2% upside from the Oct 23, 2026 close of $2.11.
What is the market cap of FATE?
As of the Oct 23, 2026 close, Fate Therapeutics's market capitalization is $254.0M, classifying it as a micro-cap company. Fate Therapeutics operates in the Healthcare sector within the Biotechnology industry.